Corporate ActionJul 21, 2026, 04:48 PM
Dyne Therapeutics Announces $300M Public Offering
AI Summary
Dyne Therapeutics, Inc. announced the commencement of an underwritten public offering of $300,000,000 of its common stock. The company also plans to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of shares. All shares in the offering will be sold by Dyne, with Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, and Raymond James serving as joint book-running managers.
Key Highlights
- Dyne Therapeutics commenced an underwritten public offering of $300,000,000 of common stock.
- The company intends to grant underwriters a 30-day option to purchase up to an additional $45,000,000 of shares.
- All shares in the proposed offering are to be sold by Dyne.
- Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, and Raymond James are joint book-running managers.
- Jones is acting as lead manager for the offering.
- The offering is being made pursuant to a shelf registration statement on Form S-3 filed March 5, 2024.
Price Impact
More from DYN